Ifoslieva 1G Combipack Injection belongs to a group of medications called ‘anti-neoplastic'. It is used in the treatment of blood cancer, breast cancer, non-small cell lung cancer, ovarian cancer (a type of cancer that begins in the ovaries), testicular cancer (cancer occurs in the testicles (testes), (which are located inside the scrotum, a loose bag of skin underneath the penis), and pancreatic cancer (a type of cancer that begins in the pancreas). Blood cancer begins in blood-forming tissue, such as the bone marrow or the immune system's cells. Examples of blood cancer are leukemia ( a blood cancer caused by a rise in the number of white blood cells in your body), lymphoma (cancer that begins in infection-fighting cells of the immune system, called lymphocytes), and multiple myeloma (cancer that forms in a type of white blood cell called a plasma cell).

Ifoslieva 1G Combipack Injection contains ‘ifosfamide’, which is an anti-cancer drug. Ifoslieva 1G Combipack Injection works by damaging the genetic material (DNA and RNA) of the cancer cells. This stops their growth and multiplication. 

Ifoslieva 1G Combipack Injection will be administered by a healthcare professional; do not self-administer. In some cases, you may experience certain common side effects such as nausea, vomiting, anemia (low number of red blood cells), hair loss, decreased white blood cell count, infection, blood in urine, CNS toxicity. Most of these side effects of Ifoslieva 1G Combipack Injection do not require medical attention and gradually resolve over time. However, if these side effects persist longer, please consult your doctor.

Do not take Ifoslieva 1G Combipack Injection if you are allergic to any other ingredients present in it. Do not self-administer Ifoslieva 1G Combipack Injection. Before taking Ifoslieva 1G Combipack Injection, talk to your doctor if you have a history of kidney disease, heart diseases, liver diseases, bone marrow suppression, cystitis, CNS toxicity. Ifoslieva 1G Combipack Injection is not recommended during pregnancy as it may affect the unborn baby. Tell your doctor if you are breastfeeding before taking Ifoslieva 1G Combipack Injection. It is not recommended for use in children under 1 year of age. 

Ifoslieva 1G Combipack Injection contains ‘ifosfamide’, which is an anti-cancer drug. It is used to treat blood cancer, breast cancer, non-small cell lung cancer, ovarian cancer, testicular cancer, and pancreatic cancer. Ifoslieva 1G Combipack Injection works by damaging the genetic material (DNA and RNA) of the cancer cells. This stops their growth and multiplication. 

Do not take Ifoslieva 1G Combipack Injection if you are allergic to any other ingredients present in it. Do not self-administer Ifoslieva 1G Combipack Injection. Before taking Ifoslieva 1G Combipack Injection, talk to your doctor if you have a history of kidney disease, heart diseases, liver diseases,  cystitis, CNS toxicity. Ifoslieva 1G Combipack Injection is not recommended during pregnancy as it may affect the unborn baby. Tell your doctor if you are breastfeeding before taking Ifoslieva 1G Combipack Injection. It is not recommended for use in children under 1 year of age. Ifoslieva 1G Combipack Injection should be used with caution in infections. Because the chances of infections are more in patients receiving this medicine. Hold the chemotherapy and start with broad-spectrum antibiotics if there are any signs and symptoms of fever. Close monitoring of the body temperature and the blood cell count is necessary. Consumption of alcohol is not recommended while receiving this Ifoslieva 1G Combipack Injection as it may increase the risk of adverse effects such as dizziness, drowsiness, abnormal muscle movements, seizures. Ifoslieva 1G Combipack Injection may cause bone marrow suppression, which lowers the white blood cell count (neutrophils) and platelets. Close monitoring of blood cell count is necessary.